Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3
Daniel Aletaha, René Westhovens, Cecile Gaujoux-Viala, Giovanni Adami, Alan Matsumoto, Paul Bird, Osvaldo Daniel Messina, Maya H Buch, Beatrix Bartok, Zhaoyu Yin, Ying Guo, Thijs Hendrikx, Gerd R Burmester, Daniel Aletaha, René Westhovens, Cecile Gaujoux-Viala, Giovanni Adami, Alan Matsumoto, Paul Bird, Osvaldo Daniel Messina, Maya H Buch, Beatrix Bartok, Zhaoyu Yin, Ying Guo, Thijs Hendrikx, Gerd R Burmester
Abstract
Objective: This analysis evaluated efficacy and safety of filgotinib, a Janus-associated kinase 1-preferential inhibitor, in methotrexate (MTX)-naive patients with rheumatoid arthritis (RA) with multiple poor prognostic factors (PPFs).
Methods: This was a post hoc analysis of the phase III, randomised, double-blind, active-controlled, FINCH 3 study (clinicaltrials.gov NCT02886728). Patients received once-daily oral filgotinib 200 or 100 mg plus once-weekly oral MTX ≤20 mg (FIL200 + MTX and FIL100 + MTX), filgotinib 200 mg monotherapy (FIL200), or oral MTX monotherapy (MTX-mono) for up to 52 weeks. PPFs investigated were seropositivity for rheumatoid factor or anticyclic citrullinated peptide antibodies, high-sensitivity C reactive protein (CRP) ≥4 mg/L, Disease Activity Score in 28 joints with CRP (DAS28(CRP)) >5.1, and presence of erosions. Filgotinib efficacy and safety in patients with all four PPFs at baseline were explored versus MTX-mono within this subgroup and compared informally with the overall population.
Results: Of 1249 patients in FINCH 3, 510 (40.8%) had all PPFs. Efficacy of FIL200 + MTX among these patients was comparable to the overall population, with higher rates of 20%/50%/70% improvement from baseline by American College of Rheumatology criteria, DAS28(CRP) <2.6, and remission; greater improvement in physical function and pain; and better inhibition of structural damage relative to MTX-mono. FIL100 + MTX and FIL200 were not consistently more efficacious versus MTX-mono. Safety of filgotinib in patients with PPFs was comparable to the overall population; no new safety signals were observed.
Conclusion: FIL200 + MTX efficacy and safety in patients with multiple PPFs were similar to the overall population.
Keywords: antirheumatic agents; arthritis; rheumatoid; therapeutics.
Conflict of interest statement
Competing interests: DA reports grants or research support from AbbVie, Merck Sharp & Dohme, Novartis, and Roche; serving as a consultant for Janssen; serving on a speaker’s bureau for Bristol-Myers Squibb, Merck Sharp & Dohme and UCB; and serving as a consultant and on a speaker’s bureau for AbbVie; Amgen; Celgene; Eli Lilly; Medac; Merck; Novartis; Pfizer; Roche; Sandoz; and Sanofi/Genzyme. RW reports grant/research support from and serving as a consultant for Celltrion; Galapagos; and Gilead Sciences, Inc. CG-V reports serving as a consultant and on a speaker’s bureau for AbbVie; Amgen; Bristol-Myers Squibb; Celgene; Eli Lilly; Galapagos; Gilead Sciences, Inc.; Janssen; Medac; Merck-Serono; Mylan; Nordic Pharma; Novartis; Pfizer; Roche; Sandoz; Sanofi; and UCB. GA reports serving as a consultant for Amgen and Theramex. AM reports grants or research support from AbbVie; Bristol-Myers Squibb; Eli Lilly; Galapagos; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen; Novartis; Pfizer; Sanofi; UCB; and Regeneron; and serving as a consultant for AbbVie; Gilead Sciences, Inc; GlaxoSmithKline; and Novartis. PB reports serving as a consultant and on a speaker’s bureau for AbbVie, Celgene, Eli Lilly, Janssen, Novartis and Pfizer. ODM reports serving on a speaker’s bureau for Amgen, Pfizer and Americas Health Foundation. MHB reports grants or research support from Pfizer, Roche and UCB; and serving as a consultant for AbbVie; Eli Lilly; Gilead Sciences, Inc; Serono; Sandoz; and Sanofi. BB, ZY and YG are employees and shareholders of Gilead Sciences, Inc. TH is an employee and shareholder of Galapagos BV. GRB reports serving as a consultant and on a speaker’s bureau for AbbVie; Eli Lilly; Pfizer; and Gilead Sciences, Inc.
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Figures
References
- Smolen JS, Landewé RBM, Bijlsma JWJ, et al. . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020;79:685–99. 10.1136/annrheumdis-2019-216655
- Vastesaeger N, Xu S, Aletaha D, et al. . A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology 2009;48:1114–21. 10.1093/rheumatology/kep155
- Visser K, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, et al. . A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the best study. Ann Rheum Dis 2010;69:1333–7. 10.1136/ard.2009.121160
- Smolen JS, Han C, van der Heijde DMFM, et al. . Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 2009;68:823–7. 10.1136/ard.2008.090019
- Smolen JS, Van Der Heijde DMFM, St Clair EW, et al. . Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006;54:702–10. 10.1002/art.21678
- Van Rompaey L, Galien R, van der Aar EM, et al. . Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol 2013;191:3568–77. 10.4049/jimmunol.1201348
- Genovese MC, Kalunian K, Gottenberg J-E, et al. . Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the finch 2 randomized clinical trial. JAMA 2019;322:315–25. 10.1001/jama.2019.9055
- Kavanaugh A, Kremer J, Ponce L, et al. . Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (Darwin 2). Ann Rheum Dis 2017;76:1009–19. 10.1136/annrheumdis-2016-210105
- Westhovens R, Taylor PC, Alten R, et al. . Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (Darwin 1). Ann Rheum Dis 2017;76:998–1008. 10.1136/annrheumdis-2016-210104
- Combe B, Kivitz A, Tanaka Y, et al. . Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis 2021;80:848–58. 10.1136/annrheumdis-2020-219214
- Westhovens R, Rigby WFC, van der Heijde D, et al. . Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled finch 3 trial. Ann Rheum Dis 2021;80:727–38. 10.1136/annrheumdis-2020-219213
- Felson DT, Anderson JJ, Boers M, et al. . American College of rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727–35. 10.1002/art.1780380602
- Aletaha D, Smolen J. The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23:S100–8.
- Felson DT, Smolen JS, Wells G, et al. . American College of Rheumatology/European League against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011;63:573–86. 10.1002/art.30129
- Prevoo ML, van 't Hof MA, Kuper HH, et al. . Modified disease activity scores that include twenty-eight-joint counts. development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8. 10.1002/art.1780380107
- Fries JF, Spitz P, Kraines RG, et al. . Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137–45. 10.1002/art.1780230202
- Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982;9:789–93.
- van der Heijde D. How to read radiographs according to the Sharp/van Der Heijde method. J Rheumatol 2000;27:261–3.
- Genovese MC, Winthrop K, Tanaka Y. Integrated safety analysis of filgotinib treatment for rheumatoid arthritis from 7 clinical trials. Ann Rheum Dis 2020;79:320. 10.1136/annrheumdis-2020-eular.267
Source: PubMed